1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Allergy Therapeutics plc

Allergy Therapeutics plc

AGY.L
Allergy Therapeutics plcGB flagLondon Stock Exchange
6.72
GBp
+0.02
- -
338.82MMarket Cap
Allergy Therapeutics plc
AGY.L
(London Stock Exchange)

Recent

price

6.72

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.14
0.13
0.13
0.1
0.09
0.09
0.09
0.11
0.11
0.12
0.12
0.13
0.11
0.09
0.01
0.01
Revenue per Share
- -
-0.01
- -
- -
- -
- -
-0.02
- -
-0.01
0.01
0.01
- -
-0.02
-0.06
-0.01
-0.01
Basic EPS, GAAP
- -
-0.01
- -
- -
- -
- -
-0.02
- -
-0.01
- -
0.02
0.01
-0.03
-0.05
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.33
-0.32
-0.31
-0.24
-0.22
-0.21
-0.2
-0.19
-0.2
-0.19
-0.18
-0.17
-0.18
-0.24
-0.05
-0.05
Book Value per Share
- -
-0.01
0.03
0.03
0.03
0.06
0.04
0.04
0.03
0.05
0.06
0.07
0.05
- -
- -
-0.01
Tangible Book Value per Share
293
311
327
408
452
475
570
592
595
633
636
639
643
670
3,743
4,766
Basic Weighted Avg Shares
41
42
41
39
42
43
49
64
68
74
78
84
73
60
55
55
Sales/Revenue/Turnover
5.66
0.28
2.65
1.7
2.88
1.68
-24.64
-2.96
-9.85
5.96
10.62
4.78
-16.83
-58.58
-61.63
-51.16
Operating Margin (%)
1
2
2
1
1
1
2
2
2
2
4
4
4
4
4
4
Depreciation Expense
1
-3
1
1
1
- -
-13
-2
-8
3
7
3
-14
-43
-39
-40
Net Income, GAAP
- -
- -
- -
- -
31.64
83.49
- -
- -
- -
19.24
12.55
21.08
- -
- -
- -
- -
Effective Tax Rate (%)
1.44
-6.41
1.99
1.61
1.77
0.25
-26.95
-3.87
-11.02
4.7
9.03
3.42
-18.93
-72.28
-69.97
-72.91
Profit Margin (%)
5
4
5
7
8
26
25
23
16
30
37
40
24
15
15
7
Working Capital
11
12
- -
- -
- -
1
3
3
2
2
10
9
8
34
29
58
LT Debt
4
2
15
15
15
34
30
30
23
38
44
49
38
4
7
-28
Total Equity
- -
- -
- -
- -
5.35
0.46
- -
- -
- -
10.11
14.29
5.18
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
-0.97
-0.15
- -
- -
- -
-3.1
-6.94
-3.34
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-46.14%
-100.94%
-483.27%
Free Cash Flow
-72.43%
-66.2%
-11.28%
Net Income, GAAP
-1,255.38%
-86.04%
3.91%
Sales/Revenue/Turnover
3.33%
-6.33%
-0.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
55
2025
- -
- -
- -
- -
55
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
The United Laboratories International Holdings Limited (ULIHF)
Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)
Excelsior Biopharma Inc. (6496.TWO)
Alvotech (ALVO)
Hemp, Inc (HEMP)
Gour Medical S.A. (MLGML.PA)
Business
Allergy Therapeutics plc stands as a commercial biotechnology enterprise dedicated to the research, development, and provision of treatments for allergic conditions. The company markets both injectable and sublingual allergen-specific immunotherapies, alongside diagnostic solutions. Its product range addresses common allergies, including those stemming from grasses, weeds, trees, and insect venoms, as well as advancing therapies for house dust mite and peanut allergies. Noteworthy offerings feature treatments like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, and the developing VLP Peanut vaccine candidate. The firm distinguishes itself by focusing on ultra-short course and aluminum-free immunotherapies designed to enhance patient adherence and treatment efficacy. Its commercial operations span key European territories, including Central Europe, Southern Europe, and the United Kingdom, supplemented by international distribution channels. Recent developments include exploring a potential dual listing on the Hong Kong Stock Exchange, ongoing progress in the Grass MATA MPL immunotherapy program, including a Marketing Authorisation Application in Germany and a pediatric Phase III trial, and positive advancements in the VLP Peanut allergy vaccine trial. Allergy Therapeutics plc was established in 2004 and maintains its principal offices in Worthing, United Kingdom.

Company News

APIChatGPT

  • globenewswire.com

    Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight